Logo

DYCQ

DT Cloud Acquisition Corporation

DYCQ

DT Cloud Acquisition Corporation • NASDAQ
$11.18 ▼ -0.72% (-0.08)
Market Cap $32.37 M
52w High $14.30
52w Low $10.38
Dividend Yield 0%
P/E 44.72
Volume 990
Outstanding Shares 2.90M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $0 ▼ $-242.147K ▼ 0% $-0.09 ▼ $-331.511K ▼
Q2-2025 $0 $269.124K ▼ $234.657K ▼ 0% $0.035 ▼ $-269.124K ▲
Q1-2025 $0 $288.262K ▲ $452.085K ▼ 0% $0.051 ▼ $-288K ▼
Q4-2024 $0 $195.829K ▲ $632.803K ▼ 0% $0.071 ▼ $-196K ▼
Q3-2024 $0 $157.61K $760.262K 0% $0.085 $-158K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.598M ▲ $1.621M ▼ $3.282M ▲ $-3.259M ▼
Q2-2025 $0 $9.103M ▼ $3.016M ▲ $6.088M ▼
Q1-2025 $0 ▼ $53.691M ▼ $2.569M ▲ $51.122M ▼
Q4-2024 $152.021K ▼ $72.514M ▲ $2.023M ▲ $70.491M ▲
Q3-2024 $167.526K $71.722M $1.864M $69.858M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-242.147K ▼ $-49.35K ▲ $7.549M ▼ $-7.5M ▲ $0 $-49.35K ▲
Q2-2025 $234.657K ▼ $-344.834K ▼ $45.068M ▲ $-44.723M ▼ $0 ▲ $-344.834K ▼
Q1-2025 $452.085K ▼ $-253.559K ▼ $19.463M ▲ $-19.362M ▼ $-152.02K ▼ $-253.559K ▼
Q4-2024 $632.803K ▼ $-15.505K ▲ $1.128M ▲ $-1.134M ▼ $-15.505K ▲ $-15.505K ▲
Q3-2024 $760.262K $-161.037K $-1.5M $1.507M $-146.876K $-146.876K

Five-Year Company Overview

Income Statement

Income Statement DT Cloud Acquisition (DYCQ) is a blank‑check SPAC, so its income statement is essentially empty from a business‑operations standpoint. It has no real revenue, no cost of goods, and no normal operating profit, which is typical for SPACs before they complete a merger. The earnings per share swings you see are mostly driven by accounting items related to the SPAC structure, not by an underlying business. In practical terms, the current income statement tells you almost nothing about the earning power of the future combined company with Maius; that will depend entirely on Maius’s ability to advance its drug pipeline and, much later, potentially generate product sales.

Balance Sheet

Balance Sheet The current balance sheet is very simple: a small base of assets funded by equity and essentially no debt, which is standard for a newly listed SPAC. There are no meaningful operating assets like factories, product inventories, or patents booked under DYCQ at this stage. Once the merger closes, the picture will change dramatically as Maius’s research assets, intellectual property, and any cash raised in the transaction move onto the combined company’s balance sheet. The quality of that future balance sheet will hinge on how much cash actually comes in through the deal and how quickly Maius spends it on research and development.

Cash Flow

Cash Flow Cash flow data are basically flat, which fits a SPAC that does not yet run a real business. There is no operating cash coming in from customers and no meaningful investing or financing cash movements beyond the SPAC’s structural activities. After the merger, the cash flow profile will flip: Maius is a clinical‑stage drug developer, so it will likely consume cash for trials, staff, and R&D infrastructure, with no offsetting product revenue for some time. The company’s ability to maintain healthy cash balances will depend on the merger proceeds and any future capital raises, rather than internal cash generation, at least in the near and medium term.

Competitive Edge

Competitive Edge On its own, DYCQ does not have a competitive position; it is simply a financing vehicle. The competitive story belongs to Maius Pharmaceutical, the intended merger partner. Maius operates in highly competitive areas—cancer, autoimmune, and infectious diseases—where many global and regional biotechs and large pharma players are active. Its main potential strengths lie in an integrated drug development platform designed to speed up discovery, and in a pipeline that spans both small‑molecule and peptide drugs, giving it flexibility in how it attacks disease targets. However, as a clinical‑stage company with no approved drugs yet, it faces the usual biotech challenges: intense competition for the same targets, scientific and clinical trial risk, regulatory hurdles, and the need to stand out in crowded therapeutic areas such as lymphoma and other B‑cell cancers.

Innovation and R&D

Innovation and R&D All meaningful innovation here sits with Maius. The company’s core idea is an integrated platform that combines chemical screening (finding promising drug compounds) with drug delivery optimization (getting those compounds into the body in an effective way). If this platform truly shortens development timelines or improves success rates, it could be a real differentiator. The focus on both small molecules and peptides broadens the types of diseases and biological pathways it can address. The named BTK inhibitor candidate for lymphoma shows that Maius is targeting validated mechanisms where better or safer next‑generation drugs could gain traction. Still, most details about the platform, pipeline breadth, and clinical data are not yet fully public, so the actual strength of the R&D engine remains to be proven through trial results and regulatory interactions over the coming years.

Summary

Today, DYCQ is essentially a shell with clean but minimal financials and no operating business, which is exactly what a SPAC is designed to be. The real story is the planned merger with Maius Pharmaceutical, a clinical‑stage biopharma company. After the deal, the financial profile will shift from a quiet, almost empty income statement and cash flow to a classic early‑stage biotech pattern: heavy spending on research and development, limited (or no) product revenue for some time, and strong dependence on external funding. Future performance will largely depend on three things: successful completion of the merger and regulatory clearances, Maius’s ability to generate solid clinical trial data and move drug candidates through approval, and its capacity to secure enough capital to support a long development runway. Until those pieces play out, the current numbers for DYCQ mainly reflect its role as a financing vehicle rather than a functioning operating company.